US 12,642,851 B2 · Self-assembling nanoparticles

Self-assembling nanoparticles

AssigneesBarinthus Biotherapeutics North America, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services

InventorsGeoffrey Martin Lynn, Christopher Martin O'Brien Garliss, Andrew Scott Ishizuka, Hugh Clarke Welles

Life of this patent

Estimating the term…

Abstract

The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-[E1]-A-[E2]-[U]-H and H-[U]-[E1]-A-[E2]-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker, [ ] denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.

Claims25

Dependent claims

A compound of Formula (1):

wherein
is an antigen (A), wherein each R8 is independently an amino acid side chain, and a is an integer number of amino acids, and
wherein A comprises an amino acid sequence selected from the group consisting of:
(SEQ ID NO:
464)
QGIIQPEQPAQLEVI,
(SEQ ID NO:
486)
QLQPFPQPELPYPQPQLPYPQPQPFR,
(SEQ ID NO:
487)
PQLPYPQPELPYPQPQPFRPEQPYPQPQP,
(SEQ ID NO:
488)
PQPQQPEQPFPQPEQEFPQPQQPQQSFPEQQPPL,
(SEQ ID NO:
489)
PQQPFPQPEQPFCQQPQ,
(SEQ ID NO:
490)
QQFLQPEQPFPQQPEQPYPQQPEQPFPQPQQ,
(SEQ ID NO:
491)
QQFSQPEQEFPQPQQPQQSFPEQQPPF,
(SEQ ID NO:
492)
PTPLQPEQPFPQQPQQPQQPFPQPEQPFPWQPQ,
(SEQ ID NO:
493)
SSPLQPEQPFPQQPQQPFPEQPQQPQ,
(SEQ ID NO:
494)
QSIPQPEQPFPQPEQPFPQSQE,
(SEQ ID NO:
495)
PQQPFPQQPQQIIPQ,
(SEQ ID NO:
496)
PQQPIPEQPQPYPEQPQPYPQQ,
and
(SEQ ID NO:
497)
PQQPFPQPEQPFBQQPQ, wherein B represents
alpha-aminobutyric acid,

41 more elements

A composition comprising a compound of Formula (1):

wherein
is an antigen (A), wherein each R8 is independently an amino acid side chain, and a is an integer number of amino acids,
wherein A comprises an amino acid sequence selected from the group consisting of:
(SEQ ID NO:
464)
QGIIQPEQPAQLEVI,
(SEQ ID NO:
484)
QQPPFSEQEQPVLPQ,
(SEQ ID NO:
486)
QLQPFPQPELPYPQPQLPYPQPQPFR,
(SEQ ID NO:
487)
PQLPYPQPELPYPQPQPFRPEQPYPQPQP,
(SEQ ID NO:
488)
PQPQQPEQPFPQPEQEFPQPQQPQQSFPEQQPPL,
(SEQ ID NO:
489)
PQQPFPQPEQPFCQQPQ,
(SEQ ID NO:
490)
QQFLQPEQPFPQQPEQPYPQQPEQPFPQPQQ,
(SEQ ID NO:
491)
QQFSQPEQEFPQPQQPQQSFPEQQPPF,
(SEQ ID NO:
492)
PTPLQPEQPFPQQPQQPQQPFPQPEQPFPWQPQ,
(SEQ ID NO:
493)
SSPLQPEQPFPQQPQQPFPEQPQQPQ,
(SEQ ID NO:
494)
QSIPQPEQPFPQPEQPFPQSQE,
(SEQ ID NO:
495)
PQQPFPQQPQQIIPQ,
(SEQ ID NO:
496)
PQQPIPEQPQPYPEQPQPYPQQ,
and
(SEQ ID NO:
497)
PQQPFPQPEQPFBQQPQ,
wherein B represents alpha-aminobutyric acid,
and wherein the composition comprises two or more unique compounds of Formula (1).

45 more elements

A composition comprising twelve or more peptides selected from:

i) a peptide having the amino acid sequence of QGIIQPEQPAQLEVI (SEQ ID NO:
464),
ii) a peptide having the amino acid sequence of QQPPFSEQEQPVLPQ (SEQ ID NO:
484),
iii) a peptide having the amino acid sequence of QPPFSQQQESPESQQ (SEQ ID NO:
485),
iv) a peptide having the amino acid sequence of QLQPFPQPELPYPQPQLPYPQPQPFR (SEQ ID NO:486),
v) a peptide having the amino acid sequence of PQLPYPQPELPYPQPQPFRPEQPYPQPQP (SEQ ID NO:487),
vi) a peptide having the amino acid sequence of PQPQQPEQPFPQPEQEFPQPQQPQQSFPEQQPPL (SEQ ID NO:488),
vii) a peptide having the amino acid sequence of PQQPFPQPEQPFCQQPQ (SEQ ID NO:489),
viii) a peptide having the amino acid sequence of QQFLQPEQPFPQQPEQPYPQQPEQPFPQPQQ (SEQ ID NO:490),
ix) a peptide having the amino acid sequence of QQFSQPEQEFPQPQQPQQSFPEQQPPF (SEQ ID NO:491),
x) a peptide having the amino acid sequence of PTPLQPEQPFPQQPQQPQQPFPQPEQPFPWQPQ (SEQ ID NO:492),
xi) a peptide having the amino acid sequence of SSPLQPEQPFPQQPQQPFPEQPQQPQ (SEQ ID NO:493),
xii) a peptide having the amino acid sequence of QSIPQPEQPFPQPEQPFPQSQE (SEQ ID NO:494),
xiii) a peptide having the amino acid sequence of PQQPFPQQPQQIIPQ (SEQ ID NO:
495),
xiv) a peptide having the amino acid sequence of PQQPIPEQPQPYPEQPQPYPQQ (SEQ ID NO:
496), and
xv) a peptide having the amino acid sequence of PQQPFPQPEQPFBQQPQ, wherein B represents alpha-aminobutyric acid (SEQ ID NO:
497).

18 more elements

Dependencies are inferred from the claim text.

Facts

Application

19/067,426Filed 28 Feb 2025 · continuation

Priority

25 Oct 2022

Published

US 2025/0242015 A131 Jul 2025

Granted

2 Jun 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

A61K 39/385
Medicinal preparations containing antigens or antibodies: haptens or antigens, bound to carriers
A61K 47/6929
The form being a solid microparticle having no hollow or gas-filled cores: the form being a nanoparticle, e.g. an immuno-nanoparticle
A61K 39/35
Medicinal preparations containing antigens or antibodies: allergens
A61K 47/545
The modifying agent being an organic compound: heterocyclic compounds

Family

Application63/380,931Us provisional application · filed 25 Oct 2022

Application18/494,491Parent of this continuation · filed 25 Oct 2023

US 2025/0242015 A1Pre-grant publication · published 31 Jul 2025

US 2024/0269269 A1Published application

US 12,642,851 B2This patent

From the US filing history. Foreign family members aren’t listed.